![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC17A9 |
Gene summary for SLC17A9 |
![]() |
Gene information | Species | Human | Gene symbol | SLC17A9 | Gene ID | 63910 |
Gene name | solute carrier family 17 member 9 | |
Gene Alias | C20orf59 | |
Cytomap | 20q13.33 | |
Gene Type | protein-coding | GO ID | GO:0001408 | UniProtAcc | H0UI90 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63910 | SLC17A9 | S43 | Human | Liver | Cirrhotic | 2.74e-03 | -4.55e-02 | -0.0187 |
63910 | SLC17A9 | HCC1_Meng | Human | Liver | HCC | 3.37e-62 | 1.84e-01 | 0.0246 |
63910 | SLC17A9 | HCC2_Meng | Human | Liver | HCC | 1.16e-14 | 1.20e-01 | 0.0107 |
63910 | SLC17A9 | S015 | Human | Liver | HCC | 8.07e-11 | 5.03e-01 | 0.2375 |
63910 | SLC17A9 | S016 | Human | Liver | HCC | 7.45e-04 | 2.57e-01 | 0.2243 |
63910 | SLC17A9 | S027 | Human | Liver | HCC | 6.70e-09 | 6.78e-01 | 0.2446 |
63910 | SLC17A9 | S028 | Human | Liver | HCC | 2.64e-22 | 9.52e-01 | 0.2503 |
63910 | SLC17A9 | S029 | Human | Liver | HCC | 9.20e-20 | 9.27e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00159316 | Liver | Cirrhotic | nucleobase-containing compound transport | 87/4634 | 222/18723 | 1.25e-06 | 2.52e-05 | 87 |
GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
GO:1901264 | Liver | HCC | carbohydrate derivative transport | 48/7958 | 80/18723 | 1.19e-03 | 6.62e-03 | 48 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC17A9 | SNV | Missense_Mutation | rs749830259 | c.166G>A | p.Gly56Ser | p.G56S | Q9BYT1 | protein_coding | tolerated(0.1) | benign(0.21) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC17A9 | SNV | Missense_Mutation | rs768086850 | c.500N>T | p.Thr167Met | p.T167M | Q9BYT1 | protein_coding | tolerated(0.07) | probably_damaging(0.981) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLC17A9 | SNV | Missense_Mutation | c.895N>G | p.His299Asp | p.H299D | Q9BYT1 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
SLC17A9 | SNV | Missense_Mutation | c.157N>A | p.Gln53Lys | p.Q53K | Q9BYT1 | protein_coding | tolerated(0.38) | benign(0.007) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
SLC17A9 | SNV | Missense_Mutation | c.1223N>A | p.Ala408Asp | p.A408D | Q9BYT1 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC17A9 | SNV | Missense_Mutation | rs778185586 | c.799N>A | p.Glu267Lys | p.E267K | Q9BYT1 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3972-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
SLC17A9 | SNV | Missense_Mutation | novel | c.481N>A | p.Ala161Thr | p.A161T | Q9BYT1 | protein_coding | tolerated(0.5) | benign(0.104) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC17A9 | SNV | Missense_Mutation | novel | c.727N>A | p.Ala243Thr | p.A243T | Q9BYT1 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SLC17A9 | SNV | Missense_Mutation | rs564928264 | c.926C>T | p.Thr309Met | p.T309M | Q9BYT1 | protein_coding | tolerated(0.15) | benign(0.067) | TCGA-F4-6809-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SLC17A9 | SNV | Missense_Mutation | c.935A>C | p.Lys312Thr | p.K312T | Q9BYT1 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
63910 | SLC17A9 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 340590235 |
Page: 1 |